Open an account

Check Cap

MBAI · NASDAQ

$2.07+$0.015 (+0.73%)TodayMarket closed ·
Prev close $2.05

About MBAI

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule systems for colorectal cancer screening. Check Cap Ltd develops C-Scan, a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer to enable early intervention and cancer prevention. Its capsule-based screening technology aims to increase screening adherence worldwide. The system utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps and other structural abnormalities. C-Scan is a non-invasive capsule that is propelled through the gastrointestinal tract by natural motility. C-Scan is comprised of three main components: C-Scan Cap, an ingestible X-ray scanning capsule; C-Scan Track, three miniaturized patches worn on the patient’s back for integrated positioning, control and data recording; and C-Scan View, a proprietary software to process and represent 2D and 3D maps of the inner surface of the colon.

Employees
85
Headquarters
Isfiya, Haifa
Listed
Feb 19, 2015
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
check-cap.com

MBAI key statistics

Market cap
31.58M
Price-earnings ratio
0.44
Dividend yield
—
Average volume
21.02K
Volume
8.04K
Open price
$2.02
High today
$2.09
Low today
$2.04
52 Week high
$27.44
52 Week low
$2.04

Check Cap (MBAI) at a glance

Check Cap (MBAI) last traded at $2.07, with a market cap of 31.58M and a price-to-earnings ratio of 0.44.

Today the stock has traded between $2.04 and $2.09. The current price is 1.2% above the day's low and 1.1% below its high.

Volume so far is 8.04K shares, below the average of 21.02K shares a day.

Over the past year Check Cap has ranged from $2.04 to $27.44, and now sits 0% of the way up that range.

Check Cap met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY23 it reported -$3.08 per share against an estimate of -$2.11.

The average analyst price target is $10.20, 393.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $10.20
Low
$10.10
Now
$2.07
High
$10.50

MBAI earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 31.9% on average.

  1. Q4 FY21: reported -$8.40 per share against an estimate of -$4.28
  2. Q1 FY22: reported -$8.40 per share against an estimate of -$8.57
  3. Q2 FY22: reported -$5.60 per share against an estimate of -$7.14
  4. Q3 FY22: reported -$0.28 per share against an estimate of -$6.43
  5. Q4 FY22: reported -$4.45 per share against an estimate of -$4.86
  6. Q1 FY23: reported -$5.32 per share against an estimate of -$3.89
  7. Q2 FY23: reported -$6.58 per share against an estimate of -$3.21
  8. Q3 FY23: reported -$3.08 per share against an estimate of -$2.11

MBAI news

  • Surbhi Jain

    Tesla’s Optimus Is Riding a Robotics Boom. Many Startups Could Lose Value

  • Press releaseGlobe Newswire

    Humanoid Global Highlights MBody AI’s Completion of Nasdaq Transaction and Commercial Robotics Deployment at Mohegan Sun

  • Surbhi Jain

    EXCLUSIVE: Robotics Has A Dell-HP Problem—and This AI Company Wants To Solve It

  • Surbhi Jain

    EXCLUSIVE: The Robot Arms Race Has A New Battlefield — Casinos

  • Rishabh Mishra

    Stock Market Today: Dow, S&P 500 Futures Fell as Trump Says US Is 'Only Semi-Negotiating' With Iran—T. Rowe, Plug Power, BIO-Key in Focus (UPDATED)

  • Press releaseGlobe Newswire

    Check-Cap: MBody AI Advances Its Robot Fleet Operating System with Multi-Robot Control

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.